{"id":3154,"date":"2026-09-15T08:53:00","date_gmt":"2026-09-15T12:53:00","guid":{"rendered":"https:\/\/www.insilens.com\/?p=3154"},"modified":"2026-09-15T19:59:13","modified_gmt":"2026-09-15T23:59:13","slug":"copernicus-tests-prophylaxis-with-subcutaneous-amivantamab","status":"publish","type":"post","link":"https:\/\/www.insilens.com\/?p=3154","title":{"rendered":"COPERNICUS Tests Prophylaxis With Subcutaneous Amivantamab"},"content":{"rendered":"

\"\"<\/p>\n

Company<\/strong><\/p>\n

Johnson & Johnson Innovative Medicine \/ Janssen Biotech<\/p>\n

Event Type<\/strong><\/p>\n

Clinical Trial Results (Phase IIb Interim Analysis)<\/p>\n

Modality<\/strong><\/p>\n

Subcutaneous Bispecific Antibody + Oral TKI Combination With Prophylaxis Protocol<\/p>\n

Asset<\/strong><\/p>\n

Amivantamab (RYBREVANT FASPRO) plus Lazertinib (LAZCLUZE)<\/p>\n

Target<\/strong><\/p>\n

EGFR and MET (amivantamab); EGFR (lazertinib)<\/p>\n

Disease Area<\/strong><\/p>\n

First-Line EGFR Exon 19 Deletion or L858R-Mutated Advanced Non-Small Cell Lung Cancer<\/p>\n

Summary<\/h4>\n

In a 214-patient interim analysis from the single-arm Phase IIb COPERNICUS study, first-line subcutaneous amivantamab plus lazertinib with anticoagulation and enhanced dermatologic prophylaxis produced rash, administration-related reactions, and venous thromboembolism rates of 25%, 3%, and 3%, respectively. Eight percent discontinued for adverse events at 8.3 months’ median follow-up. The results support feasibility of a mitigation package, but comparisons with historical intravenous MARIPOSA rates are nonrandomized and combine formulation, schedule, prophylaxis, and population effects.<\/p>\n

COPERNICUS enrolled untreated advanced EGFR exon 19 deletion or L858R NSCLC patients across U.S. academic and community sites. One percent discontinued because of rash or venous thromboembolism and none because of administration-related reactions. Most adverse events were Grade 1 or 2, and the company reported no new safety signal.<\/p>\n

The company contrasted these results with rash, administration-related reaction, and venous-thromboembolism rates of 55%, 55%, and 23% during the first four months of intravenous amivantamab plus lazertinib in MARIPOSA. That cross-study comparison cannot isolate the contribution of subcutaneous delivery, monthly maintenance dosing, oral anticoagulation, enhanced skin care, enrollment mix, or follow-up. The study targets 300 patients and its primary endpoint is investigator-assessed progression-free survival.<\/p>\n

Deep Analysis<\/h4>\n

One interpretation is that the integrated regimen makes amivantamab\u2013lazertinib materially more tolerable and easier to sustain. Low event and discontinuation rates support that possibility. Against it, there is no contemporaneous randomized control, and prophylactic anticoagulation exchanges venous-thromboembolism risk for bleeding risk that was not numerically detailed in the release. A second interpretation is that patient selection or follow-up accounts for some apparent improvement. Broad community enrollment argues for pragmatic relevance, but eligibility, event ascertainment, and exposure duration still differ from MARIPOSA.<\/p>\n

Company and Product Background<\/h4>\n

Janssen Biotech, a Johnson & Johnson company, manufactures RYBREVANT FASPRO, a subcutaneous EGFR\/MET bispecific antibody formulated with hyaluronidase. LAZCLUZE is an oral, brain-penetrant EGFR tyrosine-kinase inhibitor. Their first-line combination is approved for common EGFR-mutated advanced NSCLC. Toxicities include rash, infusion or administration reactions, venous thromboembolism, and interstitial lung disease.<\/p>\n

Signal Extraction<\/h4>\n
    \n
  • The dataset is directionally encouraging for regimen usability but is not a controlled demonstration of causation.<\/li>\n
  • Upgrades with:<\/strong> completion of 300-patient enrollment, longer exposure, detailed severe-event and bleeding rates, adherence data, and randomized or well-adjusted comparisons isolating each mitigation component.<\/li>\n
  • Downgrades if:<\/strong> cumulative rash, thromboembolism, bleeding, ILD, or discontinuation rises materially with time.<\/li>\n
  • Falsified if:<\/strong> reduced nominal event rates do not translate into sustained treatment, quality-of-life, or effectiveness gains in routine care.<\/li>\n<\/ul>\n

    InSilens Take<\/h4>\n

    The dataset is directionally encouraging for regimen usability, but it is not a controlled demonstration that the subcutaneous formulation or prophylaxis caused the lower rates. The strongest supported conclusion is operational: the combined strategy was feasible in a diverse U.S. cohort through 8.3 months.<\/p>\n

    Signal Assessment<\/h4>\n

    Signal strength:<\/strong> 4\/5 \u2014 a clinically relevant tolerability update for an approved first-line regimen. Importance:<\/strong> High \u2014 could materially change how a widely used combination is administered and monitored. Confidence:<\/strong> High on facts, moderate-low on interpretation \u2014 patient count, follow-up, event rates, and design are reported in the primary disclosure, but historical comparisons cannot separate multiple concurrent interventions.<\/p>\n","protected":false},"excerpt":{"rendered":"

    In a 214-patient interim analysis from the single-arm Phase IIb COPERNICUS study, first-line subcutaneous amivantamab plus lazertinib with anticoagulation and enhanced dermatologic prophylaxis produced rash, administration-related reactions, and venous thromboembolism rates of 25%, 3%,…<\/p>\n","protected":false},"author":1,"featured_media":3173,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1,11,3],"tags":[753,79,18],"class_list":["post-3154","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-all-categories","category-clinical","category-therapeutic-indication","tag-amivantamab","tag-johnson-johnson","tag-non-small-cell-lung-cancer"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3154","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=3154"}],"version-history":[{"count":2,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3154\/revisions"}],"predecessor-version":[{"id":3181,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3154\/revisions\/3181"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/3173"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=3154"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=3154"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=3154"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}